DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulation
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Levodopa-induced Dyskinesia
Conditions
Levodopa-induced Dyskinesia, Parkinson's Disease
Trial Timeline
May 31, 2022 → Dec 2, 2022
NCT ID
NCT05435729About DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulation
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulation is a phase 1 stage product being developed by Sumitomo Pharma for Levodopa-induced Dyskinesia. The current trial status is completed. This product is registered under clinical trial identifier NCT05435729. Target conditions include Levodopa-induced Dyskinesia, Parkinson's Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05435729 | Phase 1 | Completed |